Skip to main content

RADIOGENOMICA: IDENTIFICACION DE BIOMARCADORES A TRAVES DE METODOS BASADOS EN TRANSCRIPTOMICA, EPIGENOMICA E INTEGRACION DE MULTIOMICAS

PI19/01424

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA
Execution centre FUNDACION PUBLICA GALLEGA DE MEDICINA GENOMICA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Radiogenomics in lung cancer: Where are we?

  • Aguado-Barrera, Miguel E.
  • Sosa-Fajardo, Paloma
  • Gómez-Caamaño, Antonio
  • Taboada-Valladares, Begoña
  • Couñago, Felipe
  • López-Guerra, José Luis
  • Vega, Ana I.
Huge technological and biomedical advances have improved the survival and quality of life of lung cancer patients treated with radiotherapy. However, during treatment planning, a probability that the patient will experience adverse effects is assumed. Radiotoxicity is a complex entity that is largely dose-dependent but also has important intrinsic factors. One of the most studied is the genetic variants that may be associated with susceptibility to the development of adverse effects of radiotherapy. This review aims to present the current status of radiogenomics in lung cancer, integrating results obtained in association studies of SNPs (single nucleotide polymorphisms) related to radiotherapy toxicities. We conclude that despite numerous publications in this field, methodologies and endpoints vary greatly, making comparisons between studies difficult. Analyzing SNPs from the candidate gene approach, together with the study in cohorts limited by the sample size, has complicated the possibility of having validated results. All this delays the incorporation of genetic biomarkers in predictive models for clinical application. Thus, from all analysed SNPs, only 12 have great potential as esophagitis genetic risk factors and deserve further exploration. This review highlights the efforts that have been made to date in the radiogenomic study of radiotoxicity in lung cancer., Contract grant sponsor Ana Vega: supported by Spanish Instituto de Salud Carlos III (ISCIII) funding, an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds [INT20/00071; PI19/01424]; the Autonomous Government of Galicia, Consolidation and structuring program [IN607B]; the Fundación Mutua Madrileña [MMA2018-1, 2018]; and the Asociación Española Contra el Cáncer (AECC) [PRYES211091VEGA, 2021]., Peer reviewed